Researchers from the University of Liverpool have partnered with nebulizer maker Aerogen on a project called “Treatment of Respiratory Infections with inhaled AntimicrobiaLs” (TRIAL), which will develop inhaled therapies for the treatment of bacterial and viral pulmonary infections in hospitalized patients. Funding for the £1.3million project comes from the Engineering and Physical Sciences Research Council.
According to the university, Liverpool researchers Raechelle D’Sa and Jenny Hanson of the School of Engineering will oversee the project, joined by Daniela Ferreira and Elena Mitsi of the Liverpool School of Tropical Medicine.
D’Sa commented, “COVID19 will have a long lasting effect on the spread of antimicrobial resistance, resulting in a cascading adverse outcomes for health and economics, worldwide. We urgently need to find new ways of tacking viral and bacterial infections without contributing the slower moving but more deadly pandemic of antimicrobial resistance.”
Aerogen Associate Director R&D, Science and Emerging Technologies, Ronan Mac Loughlin said, “This partnership will be key in achieving the overall goal which to get this treatment to patients in the safest and quickest way possible. Through our interactions, we are looking forward to de-risking and expediting the development by bringing to bear our own experiences in pharmaceutical and combination product development. If successful, this will be a key therapy in effectively treating with respiratory infections and reducing their burden on healthcare systems globally.”
Read the University of Liverpool press release.
